The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas
Open accessAbstract
Since the identification of matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases, as being a driving factor for cancer progression and patient prognosis, MMPs have been studied extensively. Although early programs targeting MMPs were largely unsuccessful in clinical trials, they remain a viable and highly desirable therapeutic target based on preclinical studies and their role in disease progression. As information regarding the structure and function of these proteinases is compiled and biotechnology evolves, tools to develop better inhibitors are within our grasp. Improved methods for high throughput screening and in silico drug design programs have identified compounds which are highly potent, have high binding affinities, and exhibit favorable pharmacokinetic profiles. More recently, advances in drug delivery methods or compounds which bind outside the active site have brought new light to the field. In this review, we highlight the role of MMPs in cancer, clinical trials for MMP inhibitors, and novel approaches to targeting MMPs in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lakka, S. S., Rajan, M., Gondi, C. S., Yanamandra, N., Chandrasekar, N., Jasti, S. L., Adachi, Y., Siddique, K., Gujrati, M., Olivero, W. C., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205894 · Cited by 92
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Structure and function of matrix metalloproteinases and TIMPs
NAGASE, H., VISSE, R., & MURPHY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.002 · Cited by 3,409
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
Gialeli, C., Theocharis, A. D., & Karamanos, N. K. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07919.x · Cited by 1,607
Regulation of matrix metalloproteinase expression in tumor invasion
Westermarck, J., & Kähäri, V. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.8.781 · Cited by 1,494
Van Wart, H. E., & Birkedal-Hansen, H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5578 · Cited by 1,475
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Overall, C. M., & López-Otín, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc884 · Cited by 1,349
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Overall, C. M., & Kleifeld, O. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1821 · Cited by 1,214
Wilson, C. L., Ouellette, A. J., Satchell, D. P., Ayabe, T., López-Boado, Y. S., Stratman, J. L., Hultgren, S. J., Matrisian, L. M., & Parks, W. C. (1999) · Science · doi:10.1126/science.286.5437.113 · Cited by 1,074
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988 · cited 1×
“53,54 In hindsight, we can now appreciate that the clinical studies may not have been optimally designed.”
Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors
Whittaker, M., Floyd, C. D., Brown, P., & Gearing, A. J. H. (1999) · Chemical Reviews · doi:10.1021/cr9804543 · Cited by 982
The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis
Sternlicht, M. D., Lochter, A., Sympson, C. J., Huey, B., Rougier, J.-P., Gray, J. W., Pinkel, D., Bissell, M. J., & Werb, Z. (1999) · Cell · doi:10.1016/s0092-8674(00)81009-0 · Cited by 924
Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.
Itoh, T., Tanioka, M., Yoshida, H., Yoshioka, T., Nishimoto, H., & Itohara, S. (1998) · PubMed · Cited by 875
Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
Roy, R., Yang, J., & Moses, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5556 · Cited by 854
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention
Stetler-Stevenson, W. G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6870 · Cited by 842
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
Hidalgo, M., & Eckhardt, S. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.3.178 · Cited by 798
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases
Hu, J., Van den Steen, P. E., Sang, Q.-X. A., & Opdenakker, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2308 · Cited by 795
Matrix metalloproteinases: structures, evolution, and diversification
Massova, I., Kotra, L. P., Fridman, R., & Mobashery, S. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1075 · Cited by 781
Matrix metalloproteinases: multifunctional contributors to tumor progression
McCawley, L. J., & Matrisian, L. M. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01686-5 · Cited by 643
Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
Vihinen, P., & Kähäri, V. (2002) · International Journal of Cancer · doi:10.1002/ijc.10329 · Cited by 637
Rodríguez, D., Morrison, C. J., & Overall, C. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.09.015 · Cited by 560
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
Zucker, S., Cao, J., & Chen, W.-T. (2000) · Oncogene · doi:10.1038/sj.onc.1204097 · Cited by 550
Self-citationGolub, L. M., Ramamurthy, N. S., McNamara, T. F., Greenwald, R. A., & Rifkin, B. R. (1991) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/10454411910020030201 · Cited by 522
Zhang, J., Yuan, Z.-F., Wang, Y., Chen, W.-H., Luo, G.-F., Cheng, S.-X., Zhuo, R.-X., & Zhang, X.-Z. (2013) · Journal of the American Chemical Society · doi:10.1021/ja312004m · Cited by 517
Zhu, L., Kate, P., & Torchilin, V. P. (2012) · ACS Nano · doi:10.1021/nn300524f · Cited by 489
Matrix metalloproteinases: Fold and function of their catalytic domains
Tallant, C., Marrero, A., & Gomis-Rüth, F. X. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.04.003 · Cited by 463
Ii, M., Yamamoto, H., Adachi, Y., Maruyama, Y., & Shinomura, Y. (2006) · Experimental Biology and Medicine · doi:10.1177/153537020623100103 · Cited by 443
Protease inhibitors of the sulfonamide type: Anticancer, antiinflammatory, and antiviral agents
Supuran, C. T., Casini, A., & Scozzafava, A. (2003) · Medicinal Research Reviews · doi:10.1002/med.10047 · Cited by 431
Rasmussen, H. S., & McCann, P. P. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00023-5 · Cited by 413
Griffin, M. O., Fricovsky, E., Ceballos, G., & Villarreal, F. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00047.2010 · Cited by 413
Mehner, C., Hockla, A., Miller, E., Ran, S., Radisky, D. C., & Radisky, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.1932 · Cited by 368
Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis
Devy, L., Huang, L., Naa, L., Yanamandra, N., Pieters, H., Frans, N., Chang, E., Tao, Q., Vanhove, M., Lejeune, A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3255 · Cited by 355
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia
Klein, G., Vellenga, E., Fraaije, M. W., Kamps, W. A., & de Bont, E. S. J. M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.001 · Cited by 350
Alexander, C. M., Hansell, E. J., Behrendtsen, O., Flannery, M. L., Kishnani, N. S., Hawkes, S. P., & Werb, Z. (1996) · Development · doi:10.1242/dev.122.6.1723 · Cited by 338
Mori, H., Tomari, T., Koshikawa, N., Kajita, M., Itoh, Y., Sato, H., Tojo, H., Yana, I., & Seiki, M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf411 · Cited by 296
Rao, B. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053382115 · Cited by 221
Dentin Adhesion and MMPs: A Comprehensive Review
Perdigão, J., Reis, A., & Loguercio, A. D. (2013) · Journal of Esthetic and Restorative Dentistry · doi:10.1111/jerd.12016 · Cited by 215
Recent advances in MMP inhibitor design
Fisher, J. F., & Mobashery, S. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7894-9 · Cited by 215
Murphy, G., Nguyen, Q., Cockett, M. I., Atkinson, S. J., Allan, J. A., Knight, C. G., Willenbrock, F., & Docherty, A. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37419-7 · Cited by 214
Pavlaki, M., & Zucker, S. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023047431869 · Cited by 209
Architecture and function of metallopeptidase catalytic domains
Cerdà‐Costa, N., & Xavier Gomis‐Rüth, F. (2014) · Protein Science · doi:10.1002/pro.2400 · Cited by 209
Membrane type-matrix metalloproteinases (MT-MMP)
Zucker, S., Pei, D., Cao, J., & Lopez-Otin, C. (2003) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(03)54004-2 · Cited by 200
Self-citationCrystal structures of MMPs in complex with physiological and pharmacological inhibitors
Maskos, K. (2005) · Biochimie · doi:10.1016/j.biochi.2004.11.019 · Cited by 200
Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration.
Zarrabi, K., Dufour, A., Li, J., Kuscu, C., Pulkoski-Gross, A., Zhi, J., Hu, Y., Sampson, N. S., Zucker, S., & Cao, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.256644 · Cited by 188
Self-citationMatrix metalloproteinases in development and disease
Lemaître, V., & D'Armiento, J. (2006) · Birth Defects Research Part C: Embryo Today: Reviews · doi:10.1002/bdrc.20065 · Cited by 180
Dormán, G., Cseh, S., Hajdú, I., Barna, L., Kónya, D., Kupai, K., Kovács, L., & Ferdinandy, P. (2010) · Drugs · doi:10.2165/11318390-000000000-00000 · Cited by 178
Role of Matrix Metalloproteinase-9 Dimers in Cell Migration
Dufour, A., Zucker, S., Sampson, N. S., Kuscu, C., & Cao, J. P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091769 · Cited by 166
Self-citationBloomston, M., Zervos, E. E., & Rosemurgy, A. S. (2002) · Annals of Surgical Oncology · doi:10.1007/bf02574483 · Cited by 165
Matrix metalloproteases: Underutilized targets for drug delivery
Vartak, D. G., & Gemeinhart, R. A. (2007) · Journal of drug targeting · doi:10.1080/10611860600968967 · Cited by 159
Role of the hemopexin domain of matrix metalloproteinases in cell migration
Dufour, A., Sampson, N. S., Zucker, S., & Cao, J. P. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21535 · Cited by 159
Self-citationRemacle, A. G., Golubkov, V. S., Shiryaev, S. A., Dahl, R. S., Stebbins, J. L., Chernov, A. V., Cheltsov, A. V., Pellecchia, M., & Strongin, A. Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4149 · Cited by 157
Hirte, H. W., Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B. E., Tu, D., Sadura, A., Brundage, M., & Seymour, L. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.020 · Cited by 152
Zinc‐Binding Groups Modulate Selective Inhibition of MMPs
Agrawal, A., Romero‐Perez, D., Jacobsen, J. A., Villarreal, F. J., & Cohen, S. M. (2008) · ChemMedChem · doi:10.1002/cmdc.200700290 · Cited by 143
Ueda, J., Kajita, M., Suenaga, N., Fujii, K., & Seiki, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206962 · Cited by 136
Structural Basis of the Adaptive Molecular Recognition by MMP9
Cha, H., Kopetzki, E., Huber, R., Lanzendörfer, M., & Brandstetter, H. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00558-2 · Cited by 132
Dufour, A., Sampson, N. S., Li, J., Kuscu, C., Rizzo, R. C., DeLeon, J. L., Zhi, J., Jaber, N. L., Liu, E. V., Zucker, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4552 · Cited by 131
Self-citationX-ray Structure of Human proMMP-1
Jozic, D., Bourenkov, G. P., Lim, N. H., Visse, R., Nagase, H., Bode, W., & Maskos, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411084200 · Cited by 119
Park, A. J., Matrisian, L. M., Kells, A. F., Pearson, R. B., Yuan, Z., & Navre, M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52334-6 · Cited by 97
Martens, E., Leyssen, A., Aelst, I. V., Fiten, P., Piccard, H., Hu, J., Descamps, F. J., den Steen, P. E. V., Proost, P., Damme, J. V., et al. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.10.012 · Cited by 93
Lichte, A., Kolkenbrock, H., & Tschesche, H. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01206-9 · Cited by 73
Garcia, R. A., Pantazatos, D., Gessner, C. R., Go, K. V., Woods, V. L., & Villarreal, F. J. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006346 · Cited by 73
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Yang, M., Murray, M. T., & Kurkinen, M. T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.21.13527 · Cited by 57
Ohnishi, J., Ohnishi, E., Jin, M., Hirano, W., Nakane, D., Matsui, H., Kimura, A. P., Sawa, H., Nakayama, K., Shibuyà, H., et al. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.5.0638 · Cited by 40
Higashi, S., Hirose, T., Takeuchi, T., & Miyazaki, K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.441758 · Cited by 36
Natriuretic Peptide Receptor A as a Novel Target for Prostate Cancer
Wang, X., Raulji, P., Mohapatra, S. S., Patel, R. A., Hellermann, G., Kong, X., Vera, P. L., Meyer‐Siegler, K. L., Coppola, D., & Mohapatra, S. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-56 · Cited by 34
All-trans Retinoic Acid Improves Structure and Function of Diabetic Rat Skin in Organ Culture
Varani, J., Perone, P., Merfert, M. G., Moon, S. E., Larkin, D. D., & Stevens, M. J. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3510 · Cited by 34
MDI 301, a nonirritating retinoid, improves abrasion wound healing in damaged/atrophic skin
Warner, R. L., Bhagavathula, N., Nerusu, K. C., Hanosh, A. W., McClintock, S. D., Naik, M., Johnson, K. J., Ginsburg, I., & Varani, J. (2008) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2007.00338.x · Cited by 29
Zeng, W., Tahrani, A. A., Shakher, J., Varani, J., Hughes, S., Dubb, K., & Stevens, M. J. (2011) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.10.002 · Cited by 22
Subramanian, V., & Vellaichamy, E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.024 · Cited by 18
Gomis‐Rüth, F. X. (2004) · Wiley eBooks · doi:10.1002/9781119951438.eibc0523 · Cited by 1
Cited by
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
“However, ECM reduction has several limitations and systemic targeting of the ECM, which also affects healthy tissues, can induce adverse effects like thromboembolism [46,47].”
BackgroundRole of Extracellular Matrix in Development and Cancer Progression
Walker, C., Mojares, E., & Del Río Hernández, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103028 · Cited by 1,084
The extracellular matrix in tumor progression and metastasis
Eble, J. A., & Niland, S. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-09966-1 · Cited by 613
Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview
Mondal, S., Adhikari, N., Banerjee, S., Amin, S. A., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112260 · Cited by 556
Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review
Riaz, M., Riaz, M., Zhang, X., Lin, C., Wong, K., Chen, X., Zhang, G., Lu, A., & Yang, Z. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010195 · Cited by 509
Metadata
- Authors
- Cathcart, J., Pulkoski-Gross, A., & Cao, J.
- Venue
- Genes & Diseases
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 2
- Issue
- 1
- Pages
- 26-34
- ISSN
- 2352-3042 (ISSN-L)
- OpenAlex
- W2061723012
- Cited by
- 504
- References
- 75
- FWCI
- 16.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.